Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder;costo efectividad de la terapia adjunta con antisicóticos atípicos en el tratamiento agudo de desórdenes depresivos mayores

Annals of Pharmacotherapy

Volumn 46, Issue 5, 2012, Pages 642-649

  Taneja, Charu ^a   Papakostas, George I ^b   Jing, Yonghua ^c   Baker, Ross A ^d   Forbes, Robert A ^d   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Atypical antipsychotics; Cost effectiveness; Major depressive disorder

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZATROPINE MESILATE; ESCITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; LORAZEPAM; PAROXETINE; PROPRANOLOL; QUETIAPINE; SERTRALINE; VENLAFAXINE;

ADULT; AKATHISIA; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG WITHDRAWAL; FATIGUE; HEALTH CARE COST; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DRUG COMBINATIONS; DRUG COSTS; DRUG RESISTANCE; FLUOXETINE; HEALTH CARE COSTS; HUMANS; PIPERAZINES; QUINOLONES;

EID: 84861013330     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q326     Document Type: Article

References (23)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105.
2. APA. Practice guideline for the treatment of patients with major depressive disorder. Am J Psychiatry 2010;167:A34.
3. Fava M, Davidson K. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin N Am 1996;19:179-200.
4. Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000;22:153-162.
5. Gibson TB, Jing Y, Smith Carls G, et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care 2010;16:370-377.
6. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:843-853.
7. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:156-165.
8. Berman R, Fava M, Thase M, et al. Aripiprazole augmentation in major depression: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectrums 2009;14:197-206.
9. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009;70:540-549.
10. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fu-marate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antide-pressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010;13:917-932.
11. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and flu-oxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007;68:224-236.
12. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
13. Analy$ource Online. http://www.analysource.com/ (accessed 2005 Aug).
14. Medicare Resource Based Relative Value Scale [RBRVS] 2009. Salt Lake City, UT: Ingenix.
15. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-129.
16. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 2006;6:50.
17. Bax L, Yu LM, Tsuruta H, Moons KGM. Comprehensive free software for meta-analysis of causal research data. Version 1.7 2008. http://mix-for-meta-analysis.info (accessed 2004 Dec).
18. Calvert NW, Burch SP, Fu AZ, Reeves P, Thompson TR. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. J Manag Care Pharm 2006;12:322-330.
19. Yood MU, DeLorenze G, Quesenberry CP, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009; 18:791-799.
20. Yood MU, DeLorenze G, Quesenberry CP, et al. Association between atypical antipsychotics and newly diagnosed treated diabetes: does the effect differ by dose? Presented at: United States Psychiatric and Mental Health Congress, Las Vegas, NV, November 2-5, 2009.
21. Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom. Pharmacoeconomics 2000;18:143-148.
22. Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health 2001;4:16-31.
23. Kulp W, von der Schulenburg JM, Greiner W. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. Eur J Health Econ 2005;6:317-321.